This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2022) |
Names | |
---|---|
Preferred IUPAC name 1-(4-Chlorophenyl)-N-{3-cyano-4-phenyl}-5-methyl-1H-pyrazole-4-carboxamide | |
Other names AGN-PC-03MFTL; SureCN6052244; Y-320-5mg; Y-320-10mg; Y-320-25mg; Y-320-50mg; s7516; IL-17 Inhibitor | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChemSpider | |
PubChem CID | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C27H29ClN6O2 |
Molar mass | 505.01116 g/mol |
Density | 1.347 g/cm3 |
Boiling point | 631.225 °C (1,168.205 °F; 904.375 K) at 760 mmHg |
Hazards | |
Flash point | 335.553 °C (635.995 °F; 608.703 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references |
Y-320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.
Biological activity
In vitro
Y-320 also inhibits the production of IFN-γ and TNF-α by mouse CD4 T cells stimulated with IL-15, CXCL12, and anti-CD3 mAb.
In vivo
Y-320 (0.3-3 mg/kg p.o.) ameliorates collagen-induced arthritis (CIA) in mice with a reduction of IL-17 mRNA in arthritic joints, and also shows therapeutic effects on CIA in cynomolgus monkeys. Moreover, Y-320 shows a synergistic effect in combination with anti-TNF-α mAb on chronic-progressing CIA in mice.
References
- "Selleck Chemicals Y-320, IL-17 Inhibitor". 26 Sep 2014.
- Ushio H, et al. (2013). "A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys". Pharmaceuticals. 7 (1): 1–17. doi:10.3390/ph7010001. PMC 3915191. PMID 24366113.